Loading clinical trials...
Loading clinical trials...
Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients. A Prospective, Multicentric, Randomized, Controlled Trial.
In patients with type 2 diabetes, Roux-en-Y gastric bypass (RYGB), which excludes a portion of the stomach and the proximal intestine from the alimentary circuit, improves glucose metabolism more rapidly and more extensively than is expected from weight loss. The mechanisms of this unique effect of gastrointestinal exclusion appear to be complex and have not yet been clarified. A recent study unveil that intestinal uptake of ingested glucose is diminished by RYGB and restricted to the common limb, where food meets bile and other digestive fluids, resulting in an overall decrease of post prandial blood glucose excursion. the hypothesize that reducing the length of the common limb, which is rarely measured and highly variable in clinical practice, may significantly affect the metabolic outcome of gastrointestinal surgical procedures. The aim of the present study is to compare the impact of two variants of Roux-en-Y gastric bypass with a short common limb, the long alimentary limb or the long biliary limb Roux-en-Y gastric bypass, on type 2 diabetes remission in severely obese patients.
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
No
Chu Amiens Picardie
Amiens, France
Ch Boulogne-Sur-Me
Boulogne-sur-Mer, France
Hop Claude Huriez Chu Lille
Lille, France
Ch de Valenciennes
Valenciennes, France
Start Date
June 16, 2019
Primary Completion Date
June 1, 2026
Completion Date
June 1, 2026
Last Updated
December 23, 2025
396
ESTIMATED participants
Standard Roux-en-Y gastric bypass
PROCEDURE
Long alimentary limb Roux-en-Y gastric bypass
PROCEDURE
Lead Sponsor
University Hospital, Lille
Collaborators
NCT05942079
NCT03536377
NCT02680873
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions